丙酸氟替卡松、孟鲁斯特钠、酮替芬治疗儿童咳嗽变异性哮喘的临床疗效观察

目的 观察丙酸氟替卡松（Flu）、孟鲁斯特钠（Mon）与酮替芬（Ket）的不同联合用药方案治疗儿童咳嗽变异性哮喘（CVA）的效果。方法 将2015年6月至2018年1月于呼吸科门诊收治的280例CVA患儿随机分为Flu+Mon+Ket组、Flu+Mon组、Flu+Ket组、Mon+Ket组、Flu组、Mon组、Ket组（n=40）。每组根据各自的用药方案给予相应药物,疗程均为3个月。评估患儿在治疗后2个月及3个月时的咳嗽情况及评分、肺功能和药物不良反应,并随访复发情况。结果 随治疗时间,7组患儿咳嗽评分均呈下降趋势,第1秒用力呼气容积占预计值的百分比（FEV1%）、最大呼气流量占预计值的百分比（PEF%）均呈上升趋势。治疗2个月后,Flu+Mon+Ket组咳嗽评分均低于其他组,FEV1%、PEF%均高于其他组（P < 0.05）;治疗2个月后及治疗3个月后,Ket组咳嗽评分明显高于其他组,FEV1%、PEF%明显低于其他组（P < 0.05）;其他各组在治疗3个月后,组间咳嗽评分、FEV1%、PEF%比较差异均无统计学意义（P > 0.05）。7组不良反应发生率低且差异无统计学意义（P > 0.05）。Ket组咳嗽复发率明显高于其他组（P < 0.001）,其他各组间咳嗽复发率比较差异无统计学意义（P > 0.0024）。结论 Flu、Mon、Ket三药联合使用治疗儿童CVA在2个月时的疗效较两药联用及单药使用显著,且用药安全;但用药3个月后,单用Flu或单用Mon的疗效不差于联合用药;单用Ket疗效不佳,且停药后复发率较高。     

Comparison of the response of psoriasis,over a 6-month period,to clobetasol propionate and fluocinolone acetonide ointments

Summary

Twenty-nine patients with bilateral psoriasis were treated with clobetasol propionate ointment on one side of the body and fluocinolone acetonide ointment on the other in a double-blind clinical trial lasting 6 months. With one exception, after the first month of treatment, all patients responded better on the clobetasol propionate treated side. There was a tendency for any relapses to be less rapid and less severe in clobetasol propionate treated lesions. No adverse effects from either steroid were observed.     

Fluticasone in mild to moderate atopic dermatitis relapse: A randomized controlled trial

Background

The long-term efficacy of corticosteroids to prevent atopic dermatitis (AD) relapses has partially been addressed in children. This study compared an intermittent dosing regimen of fluticasone propionate (FP) cream 0.05% with its vehicle base in reducing the risk of relapse in children with stabilized AD.

经鼻腔给予丙酸睾丸酮对老年大鼠骨骼肌的改善作用

目的:探讨经鼻腔给予丙酸睾丸酮对老年大鼠骨骼肌生理功能和形态结构的改善作用.方法:老年雄性大鼠经鼻腔给予丙酸睾丸酮12周,利用倾斜面实验和水平绳实验观察大鼠的行为变化;H-E染色显示大鼠肱二头肌的形态变化.结果:老年大鼠鼻腔给予丙酸睾丸酮对体质量无明显影响;老年大鼠连续2d的倾斜面下滑角度减小,50°角下滑次数增加,水平绳悬挂时间缩短,鼻腔给予丙酸睾丸酮后连续2d的倾斜面下滑角度增加,50°角下滑次数减少,水平绳悬挂时间延长;老年大鼠单位面积内肱二头肌肌细胞间隔的比例增多,鼻腔给予丙酸睾丸酮后单位面积内肱二头肌肌细胞间隔的比例减少.结论:鼻腔给予丙酸睾丸酮可以提高老年大鼠的平衡反应能力和肌张力,增加肱二头肌肌细胞面积,对老年大鼠肌细胞的生理功能及形态结构起到一定的保护作用,为鼻腔应用丙酸睾丸酮治疗老化过程引起的肌肉减少症提供实验依据.     

复方丙酸氯倍他索联合他卡西醇治疗寻常型银屑病的疗效

目的：观察复方丙酸氯倍他索软膏与他卡西醇软膏联合治疗寻常型银屑病的疗效。方法将112例寻常型银屑病患者按照随机数字法分为研究组和对照组。对照组给予复方丙酸氯倍他索软膏,研究组给予复方丙酸氯倍他索软膏及他卡西醇软膏联合治疗,观察两组的临床治疗效果。结果研究组有效率为91.1％,明显高于对照组71.4％,差异有统计学意义（P＜0.05）。治疗后两组的上肢、躯干和下肢的靶损害部位评分较治疗前有明显改善,组间数据比较差异有统计学意义（P＜0.05）。研究组与对照组不良反应发生率为1.8％、3.5％,差异无统计学意义（P＞0.05）。结论复方丙酸氯倍他索软膏与他卡西醇软膏联合治疗寻常型银屑病效果显著,能有效改善患者临床症状,不良反应少,安全性高,值得临床应用。     

Amelioratory effects of testosterone propionate supplement on behavioral, biochemical and morphological parameters in aged rats

Testosterone has been shown to affect motor behavior and nigrostriatal dopaminergic (NSDA) system in young and adult male rats. However, it is not known whether exogenous testosterone intervention to aged male rats can ameliorate age-related motor impairment. Thus, in the present study, the open field motor behavior and adhesive tape removal motor performance as well as the expression of tyrosine hydroxylase (TH) and dopamine transporter (DAT) of NSDA system were examined in aged male rats following chronic subcutaneous injections of testosterone propionate (TP). Aged rats showed significantly reduced open field motor behavior and adhesive tape removal motor performance compared to adult rats. Chronic TP supplement significantly ameliorated the age-related motor deficits. The expression of TH and DAT of NSDA system was significantly enhanced in TP-treated aged rats revealed by RT-PCR, Western blot and immunohistochemistry analysis respectively. The results imply that chronic TP treatment may favorably improve the declined motor behavior and motor performance with aging. Testosterone propionate supplement that facilitated NSDA system may influence the maintenance of motor behavior and performance in aged rats.     

MP29-02 for the treatment of seasonal allergic rhinitis: a review of clinical pharmacology,efficacy and safety

This review presents the pharmacology, clinical efficacy and safety of MP29-02 (Dymista®), a unique product for the treatment of allergic rhinitis. Allergic rhinitis is often thought of more as a nuisance than a meaningful medical condition, and the health impact of allergic rhinitis can easily be underestimated. As a result, allergic rhinitis can be undertreated, expectations for relief may not be met, and patients may be left dissatisfied and non-compliant with their medications. MP29-02 is the only currently available allergic rhinitis medication to provide potent early-phase histamine-receptor blocking and long-term anti-inflammatory effects in a single intranasal formulation and delivery system that represents an advance in the therapy of allergic rhinitis, in particular for patients with moderate-to-severe disease.